Intratumoral immunization: a new paradigm for cancer therapy.

PubWeight™: 1.24‹?› | Rank: Top 10%

🔗 View Article (PMC 3979477)

Published in Clin Cancer Res on April 01, 2014

Authors

Aurélien Marabelle1, Holbrook Kohrt, Christophe Caux, Ronald Levy

Author Affiliations

1: Authors' Affiliations: Centre de Recherche en Cancérologie de Lyon, UMR INSERM U1052 CNRS 5286, Centre Léon Bérard, Université de Lyon, Lyon, France; and Division of Oncology, Stanford University, Department of Medicine, Stanford, California.

Associated clinical trials:

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001) | NCT01295827

A Phase 1 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) in Patients With Locally Advanced or Metastatic Solid Tumors | NCT01375842

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067) | NCT01844505

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) (CheckMate 017) | NCT01642004

Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC (CheckMate057) | NCT01673867

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025) | NCT01668784

Safety Study of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors | NCT01968109

A Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors | NCT01714739

Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma (CheckMate 066) | NCT01721772

Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | NCT01629758

Safety Study of Nivolumab by Itself or in Combination in Patients With Lymphoma or Multiple Myeloma | NCT01592370

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037) | NCT01721746

A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma | NCT01656642

Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | NCT01866319

A Phase 1/2 Study to Evaluate MEDI4736 | NCT01693562

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 | NCT01176461

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-012/KEYNOTE-012) | NCT01848834

Study of Two Doses of MK-3475 (Pembrolizumab) Versus Docetaxel in Previously-Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) | NCT01905657

A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | NCT01633970

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma | NCT01740297

Viral Therapy in Treating Patient With Liver Cancer | NCT01628640

A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab | NCT01307267

Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors | NCT01876511

Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma | NCT01103635

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor) | NCT01772004

A Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab and the Combination Nivolumab Plus Ipilimumab in Patients With Advanced Liver Cancer (CheckMate040) | NCT01658878

A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR] | NCT01846416

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | NCT01303705

A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab | NCT01975831

Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | NCT01750580

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma | NCT01471210

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma | NCT01775631

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission | NCT01096602

A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - "POPLAR" | NCT01903993

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast) | NCT01862900

Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | NCT01067287

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine | NCT01441765

Anti PD1 Antibody in Diffuse Intrinsic Pontine Glioma | NCT01952769

A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013)(KEYNOTE-013) | NCT01953692

Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | NCT01840579

Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma | NCT01456585

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN) | NCT01943461

Tremelimumab With Chemoembolization or Ablation for Liver Cancer | NCT01853618

Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer | NCT01769222

Gemcitabine and CT-011 for Resected Pancreatic Cancer | NCT01313416

NCT01642290

IL-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Patients With Merkel Cell Cancer (MCC) | NCT01440816

Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma (Tremelimumab) | NCT01843374

Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma | NCT01758458

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours | NCT01938612

In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy | NCT01976585

A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma | NCT01838200

Safety Study of Adenovirus Vector Engineered to Express hIL-12 in Combination With Activator Ligand to Treat Melanoma | NCT01397708

Trial of pIL-12 Electroporation Malignant Melanoma (IL-12MEL) | NCT01502293

A Phase II Study to Evaluate Safety and Efficacy of Combined Treatment With Ipilimumab and Intratumoral Interleukin-2 | NCT01480323

Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors | NCT01455259

Safety and Efficacy Study of DCVax-Direct in Solid Tumors | NCT01882946

Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | NCT01745354

A Study of Intratumoral Injection of Interleukin-2 and Ipilimumab in Patients With Unresectable Stages III-IV Melanoma | NCT01672450

Phase II Cancer Vaccine Trial for Patients With Follicular Lymphoma (Lymvac-1) | NCT01926639

Phase II Intratumoral IL12 Plasmid Electroporation in Cutaneous Lymphoma (CTCL) | NCT01579318

Gene Therapy in Treating Women With Metastatic Breast Cancer | NCT00849459

In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer | NCT01923233

Safety and Efficacy Study of INGN 241 Gene Therapy in Patients With In Transit Melanoma | NCT00116363

Intratumoral Injection Of Alpha-Gal Glycosphingolipids | NCT00668512

AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer | NCT01741038

Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer | NCT00072098

TNFerade Biologic to Treat Locally Advanced Prostate Cancer | NCT01048151

Articles citing this

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity. Oncotarget (2014) 0.92

Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A (2015) 0.91

In-situ tumor vaccination: Bringing the fight to the tumor. Hum Vaccin Immunother (2015) 0.90

Emerging Opportunities and Challenges in Cancer Immunotherapy. Clin Cancer Res (2016) 0.89

Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allows their intratumoral delivery and an improved tumor-growth inhibition. Oncoimmunology (2016) 0.87

Breaking Free of Control: How Conventional T Cells Overcome Regulatory T Cell Suppression. Front Immunol (2016) 0.83

Selective cell elimination in vitro and in vivo from tissues and tumors using antibodies conjugated with a near infrared phthalocyanine. RSC Adv (2015) 0.82

In Situ Tumor Vaccination by Combining Local Radiation and Tumor-Specific Antibody or Immunocytokine Treatments. Cancer Res (2016) 0.82

Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine. Hum Gene Ther (2014) 0.81

Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer (2016) 0.81

The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade. Cell Death Differ (2016) 0.80

Enhancing Cancer Immunotherapy Via Activation of Innate Immunity. Semin Oncol (2015) 0.79

Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Oncoimmunology (2015) 0.78

Mutant allele tumor heterogeneity (MATH) and head and neck squamous cell carcinoma. Head Neck Pathol (2015) 0.78

Cytokine-Enhanced Vaccine and Interferon-β plus Suicide Gene Therapy as Surgery Adjuvant Treatments for Spontaneous Canine Melanoma. Hum Gene Ther (2015) 0.78

Kick-starting the cancer-immunity cycle by targeting CD40. Oncoimmunology (2015) 0.78

Intratumoral dendritic cells in the anti-tumor immune response. Cell Mol Immunol (2015) 0.77

Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11b(+)Ly6G(+) intratumor myeloid cells through the TICAM-1 signaling pathway. Cell Death Differ (2016) 0.77

Intratumoral Infection with Murine Cytomegalovirus Synergizes with PD-L1 Blockade to Clear Melanoma Lesions and Induce Long-term Immunity. Mol Ther (2016) 0.76

A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma. J Immunother Cancer (2016) 0.76

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc Natl Acad Sci U S A (2016) 0.76

Delivering safer immunotherapies for cancer. Adv Drug Deliv Rev (2017) 0.76

Serum IgG4:IgG Ratio Predicts Recurrence of Patients with Hepatocellular Carcinoma after Curative Resection. J Cancer (2017) 0.75

Histologic Assessment of Intratumoral Lymphoplasmacytic Infiltration Is Useful in Predicting Prognosis of Patients with Hepatocellular Carcinoma. PLoS One (2016) 0.75

Flagellin is a strong vaginal adjuvant of a therapeutic vaccine for genital cancer. Oncoimmunology (2015) 0.75

Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. Oncoimmunology (2015) 0.75

Targeting Antitumor Immune Response for Enhancing the Efficacy of Photodynamic Therapy of Cancer: Recent Advances and Future Perspectives. Oxid Med Cell Longev (2016) 0.75

Intratumoral infection by CMV may change the tumor environment by directly interacting with tumor-associated macrophages to promote cancer immunity. Hum Vaccin Immunother (2017) 0.75

Articles cited by this

Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96

CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 12.24

The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90

Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med (2012) 8.46

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37

Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol (2007) 5.28

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21

Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer. Nat Med (2013) 4.86

Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17

Viral evasion and subversion of pattern-recognition receptor signalling. Nat Rev Immunol (2008) 4.16

In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med (2013) 3.83

The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop Relat Res (1991) 3.79

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res (2006) 3.38

Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35

Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. J Clin Invest (2009) 2.85

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol Res (2013) 2.76

Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc Natl Acad Sci U S A (2012) 2.61

The toll-like receptor repertoire of human B lymphocytes: inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood (2003) 2.57

Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol (2011) 2.35

Dendritic cell infiltration and prognosis of early stage breast cancer. Clin Cancer Res (2004) 2.34

Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer (2008) 2.32

The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys (2012) 2.29

BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Ann Surg (1974) 2.14

Management of nonmelanoma skin cancer in 2007. Nat Clin Pract Oncol (2007) 2.07

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med (2013) 1.96

The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95

Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer (2006) 1.91

Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science (1971) 1.80

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69

BCG and cancer. N Engl J Med (1974) 1.66

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells. J Clin Invest (2012) 1.66

Toll-like receptors in tumor immunotherapy. Clin Cancer Res (2007) 1.60

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54

Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53

CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Res (2004) 1.43

TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene (2008) 1.41

Abscopal effect in a patient with melanoma. N Engl J Med (2012) 1.39

Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin Cancer Res (2005) 1.38

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol (2012) 1.37

Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 1.34

Macrophage infiltration predicts a poor prognosis for human ewing sarcoma. Am J Pathol (2011) 1.30

CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol (2001) 1.30

Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett (2013) 1.30

Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 1.28

Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer (2007) 1.26

Intraepithelial CD8-positive T lymphocytes predict survival for patients with serous stage III ovarian carcinomas: relevance of clonal selection of T lymphocytes. Br J Cancer (2009) 1.25

Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett (2013) 1.24

The number of intratumoral dendritic cells and zeta-chain expression in T cells as prognostic and survival biomarkers in patients with oral carcinoma. Cancer (2001) 1.22

S100 positive dendritic cells in human lung tumors associated with cell differentiation and enhanced survival. Pathology (1993) 1.19

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin Cancer Res (2013) 1.18

How BCG led to the discovery of immunostimulatory DNA. Jpn J Infect Dis (1999) 1.14

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res (2013) 1.11

Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res (2012) 1.09

Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity. Cancer Immunol Immunother (2008) 1.09

Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol (2007) 1.08

Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res (2013) 1.04

Turning tumors into vaccines: co-opting the innate immune system. Immunity (2013) 0.99

Combined intralesional Bacille Calmette-Guérin (BCG) and topical imiquimod for in-transit melanoma. J Immunother (2012) 0.98

Feedback loop of immune regulation by CD4+CD25+ Treg. Immunobiology (2008) 0.93

Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy. Int J Cancer (2011) 0.92

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology (2012) 0.91

Malignant melanoma metastatic to the bladder. Regression following intratumor injection of BCG vaccine. JAMA (1974) 0.87

Antitumor activity of the DNA fraction from Mycobacterium bovis BCG. II. Effects on various syngeneic mouse tumors. J Natl Cancer Inst (1985) 0.83

Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer (1978) 0.83

Immunotherapy with BCG administered by scarification: standardization of reactions and management of side effects. Cancer (1978) 0.81

Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. Cancer (1978) 0.81

Prognostic significance of CD83 positive tumor-infiltrating dendritic cells and expression of TGF-beta 1 in human gastric cancer. Hepatogastroenterology (2011) 0.78

Prognostic significance of CD83 positive, mature dendritic cells in the gallbladder carcinoma. Oncol Rep (2005) 0.77

Articles by these authors

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med (2004) 6.91

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol (2003) 6.77

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood (2009) 5.84

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol (2010) 3.88

A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med (2005) 3.59

Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell (2010) 3.37

Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res (2009) 3.31

Structural organization of bacterial RNA polymerase holoenzyme and the RNA polymerase-promoter open complex. Cell (2002) 3.21

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77

Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. Immunity (2006) 2.62

Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood (2002) 2.52

Chemokines in cancer. Cytokine Growth Factor Rev (2002) 2.47

Altered B-cell receptor signaling kinetics distinguish human follicular lymphoma B cells from tumor-infiltrating nonmalignant B cells. Blood (2006) 2.32

Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 2.25

B-cell signaling networks reveal a negative prognostic human lymphoma cell subset that emerges during tumor progression. Proc Natl Acad Sci U S A (2010) 2.10

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood (2010) 2.06

Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. J Biol Chem (2005) 2.03

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. Blood (2011) 2.02

Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood (2005) 1.99

The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood (2006) 1.94

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer. J Clin Invest (2012) 1.92

LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol (2007) 1.88

Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood (2013) 1.86

Therapeutic effect of CD137 immunomodulation in lymphoma and its enhancement by Treg depletion. Blood (2009) 1.81

Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol (2004) 1.74

A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. Blood (2009) 1.74

BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood (2003) 1.73

Kinetics of B cell receptor signaling in human B cell subsets mapped by phosphospecific flow cytometry. J Immunol (2006) 1.72

Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma (2009) 1.71

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 1.68

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma (2009) 1.68

Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol (2006) 1.68

The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med (2003) 1.63

Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. Blood (2014) 1.58

Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci U S A (2003) 1.58

Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood (2013) 1.55

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood (2008) 1.55

Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol (2007) 1.54

Transformation of follicular lymphoma to diffuse large-cell lymphoma: alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci U S A (2002) 1.49

HGAL is a novel interleukin-4-inducible gene that strongly predicts survival in diffuse large B-cell lymphoma. Blood (2003) 1.47

Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. Eur J Immunol (2002) 1.44

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood (2011) 1.41

Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood (2002) 1.40

Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol (2002) 1.38

CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol (2005) 1.37

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res (2008) 1.36

Differences in tumor regulatory T-cell localization and activation status impact patient outcome. Cancer Res (2009) 1.35

Targeting CD137 enhances the efficacy of cetuximab. J Clin Invest (2014) 1.29

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res (2012) 1.26

Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. Trends Immunol (2010) 1.25

Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res (2011) 1.24

Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res (2011) 1.23

Vaccines for lymphomas: idiotype vaccines and beyond. Blood Rev (2008) 1.22

ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res (2012) 1.22

The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res (2004) 1.22

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood (2013) 1.20

Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer (2009) 1.19

High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. Eur J Immunol (2009) 1.19

Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A (2007) 1.19

Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk Lymphoma (2002) 1.18

Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res (2002) 1.17

TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. J Immunol (2010) 1.13

Combination strategies to enhance antitumor ADCC. Immunotherapy (2012) 1.12

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood (2013) 1.12

Cell-free production of scFv fusion proteins: an efficient approach for personalized lymphoma vaccines. Blood (2006) 1.11

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res (2013) 1.11

Targeting regulatory T cells. Target Oncol (2012) 1.10

BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol (2002) 1.09

Expression of the human germinal center-associated lymphoma (HGAL) protein identifies a subset of classic Hodgkin lymphoma of germinal center derivation and improved survival. Blood (2006) 1.09

Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma. Blood (2009) 1.08

Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood (2008) 1.07

Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood (2002) 1.07

Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology (2012) 1.05

Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. Mol Pharmacol (2003) 1.05

Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin. Blood (2003) 1.03

Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. Blood (2012) 1.03

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy. Blood (2006) 1.00

Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. Int J Cancer (2004) 1.00

Rapid expression of vaccine proteins for B-cell lymphoma in a cell-free system. Biotechnol Bioeng (2005) 0.99

Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res (2005) 0.97

A CpG-loaded tumor cell vaccine induces antitumor CD4+ T cells that are effective in adoptive therapy for large and established tumors. Blood (2010) 0.96

''Minor'' BCL2 breakpoints in follicular lymphoma: frequency and correlation with grade and disease presentation in 236 cases. J Mol Diagn (2007) 0.96

CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8α+ dendritic cells [corrected]. J Immunol (2010) 0.95

Self-antigen recognition by follicular lymphoma B-cell receptors. Blood (2012) 0.95

Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab. Leuk Lymphoma (2009) 0.95

The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities. Am J Clin Pathol (2009) 0.94

Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Trends Immunol (2011) 0.93

Higher grade transformation of follicular lymphoma: phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol (2003) 0.92

Selective resistance of CD44hi T cells to p53-dependent cell death results in persistence of immunologic memory after total body irradiation. J Immunol (2011) 0.92

Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. Oncoimmunology (2012) 0.91

Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol (2012) 0.91

A vaccine directed to B cells and produced by cell-free protein synthesis generates potent antilymphoma immunity. Proc Natl Acad Sci U S A (2012) 0.91

Cancer vaccines: pessimism in check. Nat Med (2004) 0.91

Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development. J Immunol (2002) 0.90

CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am J Pathol (2012) 0.90

Active and passive immunotherapy for lymphoma: proving principles and improving results. J Clin Oncol (2011) 0.90

Cell-free production of Gaussia princeps luciferase--antibody fragment bioconjugates for ex vivo detection of tumor cells. Biochem Biophys Res Commun (2009) 0.90